PubMed
A single ascending-dose study of muscle regulator ACE-031 in healthy volunteers
Attie KM, Borgstein NG, Yang Y, et al. Muscle Nerve. 2013
Compare
ACE-031 vs Cagrilintide
Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.
Last reviewed . By the PeptIQ team.
Observational reporting only — not medical advice. Does not recommend doses, protocols, or treatments.
ACE-031
308 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 62% · Mixed 22% · Unfavorable overall 16%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Joint comfort
-149
Recovery
-31
Digestive comfort
-151
Skin appearance
-99
Appetite control
-47
Most logged side effects
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Injection site reaction
-53
Anxiety
-132
Flushing
-6
Headache
-103
GI discomfort
-48
Self-reported dose per injection
Median bucket: 200–400 mcg · Most common: 100–200 mcg
Reports span 25–1000 mcg
25–50
4
50–100
14
100–200
18
200–400
9
400–600
6
600–1000
1
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
Common discussion topics
timing32stacking10side effects28ace-03116
How repeat users are trending
Among repeat reporters, 57% said they felt similar to their last entry, 30% more positive, and 12% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 28 days · Based on 68 repeat reporters
Cagrilintide
29 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 98% · Mixed 2% · Unfavorable overall 0%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Appetite
139
Most logged side effects
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Nausea
1
Digestive upset
1
Injection site irritation
1
Self-reported dose per injection
Median bucket: 2+ mg · Most common: 2+ mg
Reports span 0 to ≥ 2 mg (open-ended top bucket)
0–0.025 mg
41
0.2–0.4 mg
9
0.4–0.6 mg
2
0.6–1 mg
3
1–2 mg
1
2+ mg
83
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
How repeat users are trending
Among repeat reporters, 87% said they felt similar to their last entry, 13% more positive, and 0% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 142 days · Based on 23 repeat reporters
Sources (8)
Published sources linked on the ACE-031 and Cagrilintide wiki pages.
- Wiki study page →Source
- Wiki study page →Source
PubMed
Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo-controlled clinical trial
Campbell C, McMillan HJ, Mah JK, et al. Muscle Nerve. 2017
- Wiki study page →Source
PubMed
Myostatin and its Regulation: A Comprehensive Review of Myostatin Inhibiting Strategies
Baig MH, Ahmad K, Moon JS, et al. Front Physiol. 2022
- Wiki study page →Source
ClinicalTrials.gov
ACE-031 (ActRIIB-Fc) studies on ClinicalTrials.gov
ClinicalTrials.gov. Clinical trial registry. 2024
- Wiki study page →Source
PubMed
Cagrilintide, a long-acting amylin analogue, for the treatment of obesity
Lau DCW, Erondu N, Skovgaard D, et al. Lancet. 2022
- Wiki study page →Source
ClinicalTrials.gov
Cagrilintide obesity studies on ClinicalTrials.gov
ClinicalTrials.gov. Clinical trial registry. 2024
- Wiki study page →Source
PubMed
Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity
D'Ascanio AM, Mullally JA, Frishman WH. Cardiology in review. 2024
- Wiki study page →Source
PubMed
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity
Garvey WT, Blüher M, Osorto Contreras CK, et al. The New England journal of medicine. 2025